Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Marine Drugs is Scopus-indexed (Q1, CiteScore 11.6), WoS SCIE, DOAJ. Published by Multidisciplinary Digital Publishing Institute (MDPI).
Checked against the index lists dated .
ISSN 1660-3397Verify ISSN ↗
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology, Toxicology and Pharmaceutics (miscellaneous) | 2 / 57 | 97th | Q1 |
| Pharmaceutical Science | 16 / 191 | 91st | Q1 |
| Drug Discovery | 17 / 161 | 89th | Q1 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2003–present, best quartile Q1, CiteScore 11.6.
Marine Drugs is Q1 in Pharmacology, Toxicology and Pharmaceutics (miscellaneous) (rank 2 of 57), Q1 in Pharmaceutical Science (rank 16 of 191) and Q1 in Drug Discovery (rank 17 of 161), by CiteScore 2025.
Marine Drugs is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 11.6, which places it in quartile Q1 at the 97th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.044, quartile Q1, with an H-index of 188.
The publisher lists an article processing charge of about US$3,499 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Marine Drugs is published by Multidisciplinary Digital Publishing Institute (MDPI). Its ISSN is 1660-3397.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Marine Drugs has an h-index of 212 and a 2-year mean of 6.71 citations per paper (OpenAlex). Its Scopus CiteScore is 11.6, quartile Q1. On 2-year citations it ranks #1 of 52 Scopus journals in Pharmacology, Toxicology and Pharmaceutics (miscellaneous).
Marine Drugs published 487 papers in 2025; its busiest recent year was 2022 with 785. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2026), authors are most often from China (42.7%), Spain (6.8%) and South Korea (6.1%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (0.3 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.